$OCUL
OCULAR THERAPEUTIX, INC

2021 Q2 Form 10-Q Financial Statement

#000155837021010967 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $11.72M $1.569M
YoY Change 646.85% 141.38%
Cost Of Revenue $1.096M $134.0K
YoY Change 717.91% -75.72%
Gross Profit $10.62M $1.435M
YoY Change 640.21% 1364.29%
Gross Profit Margin 90.65% 91.46%
Selling, General & Admin $16.99M $11.30M
YoY Change 50.42% -8.02%
% of Gross Profit 159.99% 787.32%
Research & Development $13.86M $8.021M
YoY Change 72.78% -14.8%
% of Gross Profit 130.47% 558.95%
Depreciation & Amortization $607.0K $710.0K
YoY Change -14.51% 18.33%
% of Gross Profit 5.71% 49.48%
Operating Expenses $30.85M $19.32M
YoY Change 59.7% -10.96%
Operating Profit -$20.23M -$17.88M
YoY Change 13.12% -17.2%
Interest Expense $1.655M $1.694M
YoY Change -2.3% 4.12%
% of Operating Profit
Other Income/Expense, Net $11.75M -$18.68M
YoY Change -162.89% 554.66%
Pretax Income -$8.481M -$36.57M
YoY Change -76.81% 49.57%
Income Tax
% Of Pretax Income
Net Earnings -$8.481M -$36.57M
YoY Change -76.81% 49.54%
Net Earnings / Revenue -72.38% -2330.66%
Basic Earnings Per Share -$0.11 -$0.64
Diluted Earnings Per Share -$0.25 -$0.64
COMMON SHARES
Basic Shares Outstanding 76.32M 57.37M
Diluted Shares Outstanding 82.09M 57.37M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $191.9M $84.30M
YoY Change 127.59% 36.41%
Cash & Equivalents $191.9M $84.29M
Short-Term Investments
Other Short-Term Assets $4.817M $2.100M
YoY Change 129.38% -8.7%
Inventory $1.112M $1.067M
Prepaid Expenses
Receivables $18.73M $2.874M
Other Receivables $0.00 $0.00
Total Short-Term Assets $216.5M $90.29M
YoY Change 139.8% 38.06%
LONG-TERM ASSETS
Property, Plant & Equipment $7.042M $8.934M
YoY Change -21.18% -48.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.764M $1.800M
YoY Change -2.0% -73.53%
Total Long-Term Assets $14.18M $16.97M
YoY Change -16.4% -30.18%
TOTAL ASSETS
Total Short-Term Assets $216.5M $90.29M
Total Long-Term Assets $14.18M $16.97M
Total Assets $230.7M $107.3M
YoY Change 115.09% 19.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.881M $2.650M
YoY Change 46.45% -33.75%
Accrued Expenses $16.18M $5.769M
YoY Change 180.5% -5.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $4.100M
YoY Change -100.0%
Total Short-Term Liabilities $21.55M $13.80M
YoY Change 56.13% 36.66%
LONG-TERM LIABILITIES
Long-Term Debt $50.24M $47.30M
YoY Change 6.21% -3.07%
Other Long-Term Liabilities $78.67M $40.80M
YoY Change 92.82% 80.53%
Total Long-Term Liabilities $128.9M $88.10M
YoY Change 46.32% 23.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.55M $13.80M
Total Long-Term Liabilities $128.9M $88.10M
Total Liabilities $150.5M $101.9M
YoY Change 47.63% 25.05%
SHAREHOLDERS EQUITY
Retained Earnings -$544.6M -$441.7M
YoY Change 23.3%
Common Stock $624.9M $447.0M
YoY Change 39.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.25M $5.344M
YoY Change
Total Liabilities & Shareholders Equity $230.7M $107.3M
YoY Change 115.09% 19.58%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$8.481M -$36.57M
YoY Change -76.81% 49.54%
Depreciation, Depletion And Amortization $607.0K $710.0K
YoY Change -14.51% 18.33%
Cash From Operating Activities -$20.06M -$14.80M
YoY Change 35.51% -22.84%
INVESTING ACTIVITIES
Capital Expenditures -$127.0K -$120.0K
YoY Change 5.83% -75.51%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$127.0K -$120.0K
YoY Change 5.83% -75.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.33M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.665M 51.06M
YoY Change -94.78% 856.18%
NET CHANGE
Cash From Operating Activities -20.06M -14.80M
Cash From Investing Activities -127.0K -120.0K
Cash From Financing Activities 2.665M 51.06M
Net Change In Cash -17.52M 36.14M
YoY Change -148.47% -352.2%
FREE CASH FLOW
Cash From Operating Activities -$20.06M -$14.80M
Capital Expenditures -$127.0K -$120.0K
Free Cash Flow -$19.93M -$14.68M
YoY Change 35.75% -21.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2021Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57368292
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75996732
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76454597
dei Entity Central Index Key
EntityCentralIndexKey
0001393434
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36554
dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Address Address Line1
EntityAddressAddressLine1
24 Crosby Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-4000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76582927
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191860000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228057000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18734000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12252000
CY2021Q2 us-gaap Inventory Net
InventoryNet
1112000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1201000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4817000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4650000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
216523000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
246160000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7042000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8095000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5378000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5844000
CY2021Q2 us-gaap Assets
Assets
230707000
CY2020Q4 us-gaap Assets
Assets
261863000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3881000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2709000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16182000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14307000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1487000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1358000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
8290000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21550000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26664000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6770000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7548000
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
59901000
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
98313000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12000000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
24891000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
16936000
CY2021Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
25348000
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
24307000
CY2021Q2 us-gaap Liabilities
Liabilities
150460000
CY2020Q4 us-gaap Liabilities
Liabilities
185768000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76454597
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75996732
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
624850000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
615338000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-544611000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-539251000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
80247000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
76095000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
230707000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261863000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11718000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1569000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19061000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4178000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11718000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1569000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19061000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4178000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1096000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
134000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1988000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
953000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13859000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8021000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24786000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14119000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8391000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6153000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16477000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13283000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8603000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5145000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16268000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10321000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
31949000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
19453000
us-gaap Costs And Expenses
CostsAndExpenses
59519000
us-gaap Costs And Expenses
CostsAndExpenses
38676000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20231000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17884000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40458000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34498000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
8000
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
17000
us-gaap Investment Income Net
InvestmentIncomeNet
20000
us-gaap Investment Income Net
InvestmentIncomeNet
156000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1655000
CY2020Q2 us-gaap Interest Expense
InterestExpense
1694000
us-gaap Interest Expense
InterestExpense
3335000
us-gaap Interest Expense
InterestExpense
3327000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
13396000
CY2020Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-17007000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
38412000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-20411000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11750000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18684000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35098000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23582000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-36568000
us-gaap Net Income Loss
NetIncomeLoss
-5360000
us-gaap Net Income Loss
NetIncomeLoss
-58080000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76324367
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57368292
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76198384
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54634572
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82093599
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57368292
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81967616
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54634572
us-gaap Profit Loss
ProfitLoss
-5360000
us-gaap Profit Loss
ProfitLoss
-58080000
us-gaap Share Based Compensation
ShareBasedCompensation
7378000
us-gaap Share Based Compensation
ShareBasedCompensation
3491000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2282000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2156000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1255000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-786000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
928000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1866000
ocul Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-649000
ocul Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-537000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37415000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33650000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
374000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-287000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
38412000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-20411000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1257000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1441000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6482000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
326000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
167000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-173000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-89000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
113000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-466000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-386000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-374000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3722000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1735000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
506000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
490000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
350000
ocul Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
3201000
ocul Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
3201000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-275000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
63025000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1505000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63881000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36197000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29857000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229821000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56201000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193624000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86058000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
63000
ocul Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
318000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
76095000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
91000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3086000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
3121000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
83408000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
538000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
490000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4292000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
80247000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-3630000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12690000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1665000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-21512000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-10659000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191860000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
378000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
350000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50017000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1826000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-36568000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5344000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-544611000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, clinical trial accruals and the fair value of derivatives.  Actual results may differ from these estimates.  The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, and those of its customers, vendors, suppliers, and collaboration partners, will depend on future developments that are highly uncertain, subject to change and difficult to predict, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international customers and markets. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers and Customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Company is dependent on a small number of third-party manufacturers to supply products for research and development activities in its preclinical and clinical programs and for sales of its products. The Company’s development programs as well as revenue from future sales of its product sales could be adversely affected by a significant interruption in the supply of any of the components of these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and six months ended June 30, 2021, three specialty distributor customers accounted for 45%, 28%, and 15%, and 45%, 25% and 14%<span style="white-space:pre-wrap;">, respectively, of the Company’s total revenue, and no other customer accounted for more than 10% of the Company’s total revenue. At June 30, 2021, </span>three specialty distributor customers accounted for 51%, 27% and 14% of the Company’s total accounts receivable and no other customer accounted for more than 10% of the Company’s total accounts receivable at June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and six months ended June 30, 2020, three specialty distributor customers accounted for 48%, 16% and 14% and 41%, 19% and 14%<span style="white-space:pre-wrap;">, respectively, of the Company’s total revenue and no other customer accounted for more than 10% of total revenue. At December 31, 2020, </span>three specialty distributor customers accounted for 45%, 33% and 15% of the Company’s total accounts receivable and no other customer accounted for more than 10% of the Company’s total accounts receivable at December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191860000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84294000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193624000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86058000
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
347000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
384000
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
437000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
232000
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
328000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
585000
CY2021Q2 us-gaap Inventory Net
InventoryNet
1112000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1201000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4873000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5853000
CY2021Q2 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
2736000
CY2020Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
1438000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1077000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
868000
CY2021Q2 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1258000
CY2020Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1013000
CY2021Q2 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
5325000
CY2020Q4 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
4194000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
913000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
941000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16182000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14307000
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
98313000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
38412000
CY2021Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
59901000
CY2021Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2021Q2 ocul Debt Instrument Exit Fees Payable
DebtInstrumentExitFeesPayable
15000
CY2020Q4 ocul Debt Instrument Exit Fees Payable
DebtInstrumentExitFeesPayable
355000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
124000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
129000
CY2021Q2 us-gaap Notes Payable
NotesPayable
24891000
CY2020Q4 us-gaap Notes Payable
NotesPayable
25226000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
8290000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
24891000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
16936000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-36568000
us-gaap Net Income Loss
NetIncomeLoss
-5360000
us-gaap Net Income Loss
NetIncomeLoss
-58080000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76324367
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57368292
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76198384
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54634572
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8481000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5360000
CY2021Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1095000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2173000
CY2021Q2 us-gaap Dilutive Securities
DilutiveSecurities
-13396000
us-gaap Dilutive Securities
DilutiveSecurities
-38412000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20782000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41599000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76324367
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76198384
CY2021Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82093599
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81967616
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11049287
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9289112
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4292000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1826000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7378000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3491000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
26106000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000

Files In Submission

Name View Source Status
0001558370-21-010967-index-headers.html Edgar Link pending
0001558370-21-010967-index.html Edgar Link pending
0001558370-21-010967.txt Edgar Link pending
0001558370-21-010967-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20210630.xsd Edgar Link pending
ocul-20210630x10q.htm Edgar Link pending
ocul-20210630x10q_htm.xml Edgar Link completed
ocul-20210630xex31d1.htm Edgar Link pending
ocul-20210630xex31d2.htm Edgar Link pending
ocul-20210630xex32d1.htm Edgar Link pending
ocul-20210630xex32d2.htm Edgar Link pending
ocul-20210630xex3d1.htm Edgar Link pending
ocul-20210630_cal.xml Edgar Link unprocessable
ocul-20210630_def.xml Edgar Link unprocessable
ocul-20210630_lab.xml Edgar Link unprocessable
ocul-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending